Liver International

Papers
(The H4-Index of Liver International is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population205
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO118
Author's reply: The relationship between systemic inflammation and liver fibrogenesis in patients with cirrhosis113
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma108
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”88
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis85
Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents81
High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy79
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study79
Cover Image74
Reply to: “Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank”70
Issue Information66
63
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank62
A multi‐site, nurse‐coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia60
Effect of statins on the recurrence of hepatocellular carcinoma after liver transplantation: An illusion revealed by exposure density sampling59
59
57
Tolvaptan for difficult‐ to ‐treat ascites: Difficulties in opening doors for GWAS application56
Issue Information55
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?55
Issue Information51
Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies51
How to get away with liver innate immunity? A viruses’ tale50
DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐0150
MR elastography to predict haemodynamic response to beta‐blockers—The story is still incomplete50
Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?50
Natural history, spectrum and outcome of stage 3 AKI in patients with acute‐on‐chronic liver failure48
Improving prediction of hepatocellular carcinoma in chronic hepatitis B by machine learning: Productive relationship of medicine with computer science46
HBV cure—The light at the end of the tunnel?45
45
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology45
Hepatitis delta virus infection in the Middle East42
Vaccination against COVID‐19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis41
COVID‐19, adaptative immune response and metabolic‐associated liver disease41
Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression41
High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis41
Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma39
Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort38
Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon38
0.11267399787903